Alliance for Pandemic Preparedness

June 12, 2020

Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Geneva, Switzerland (SEROCoV-POP): A Population-Based Study

Category:

Topic:

  • *A population-based household serosurvey conducted in Geneva, Switzerland found that accounting for test validity (sensitivity and specificity) using Bayesian methods, seroprevalence increased over the first three weeks of the repeated survey (3.8% in week 1, 8.5% in week 2, and 10.9% in week 3).  
  • Seropositivity was significantly lower among those 5-9 years old (RR=0.32, 95% CI 0.11-0.63) and those over 65 (RR=0.5, 95% CI 0.28-0.78) compared with those 20-49. The authors estimated 11.6 infections for every reported case.  

Stringhini et al. (June 2020). Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Geneva, Switzerland (SEROCoV-POP): A Population-Based Study. The Lancet. https://doi.org/10.1016/S0140-6736(20)31304-0 

* This study was first included in the Lit Rep as a pre-print on May 7, 2020. Findings are largely unchanged.